Erythropoietin and long-acting erythropoiesis stimulating agent ameliorate non-alcoholic fatty liver disease by increasing lipolysis and decreasing lipogenesis via EPOR/STAT pathway

Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity

Jeffrey D. Browning, Lidia S. Szczepaniak, Robert L. Dobbins et al. · Hepatology · 2004 · 3.7K citations

Medicine, Endocrinology, Internal Medicine +12

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Arun J. Sanyal, Naga Chalasani, Kris V. Kowdley et al. · New England Journal of Medicine · 2010 · 3.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7

Nonalcoholic Fatty Liver Disease

Giulio Marchesini, Mara Brizi, Giampaolo Bianchi et al. · Diabetes · 2001 · 2.6K citations · Full text

Medicine, Pathology, Hepatology +11

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

Christopher D. Williams, Joel Z. Stengel, Michael Asike et al. · Gastroenterology · 2010 · 2.2K citations · Full text

Medicine, Internal Medicine, Hepatology +14

A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis

Renata Belfort, Stephen A. Harrison, Kenneth Brown et al. · New England Journal of Medicine · 2006 · 1.8K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13